Michael Burry’s REGN Holdings & Trades

First Buy
Q2 2025
Duration Held
2 Quarters
Largest Add
Q2 2025
+15,000 Shares
Current Position
0 Shares
$0 Value

Michael Burry's REGN Position Overview

Michael Burry (via Scion Asset Management, LLC) currently holds 0 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $0, representing 0.00% of the portfolio. First purchased in 2025-Q2, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Michael Burry has initiated a new position in REGN, representing a fresh investment thesis on this company. Largest reduction occurred in Q3 2025, reducing 15,000 shares.

Analysis based on 13F filings available since 2013 Q2

Michael Burry's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Michael Burry

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2025 +15,000 New Buy 15,000 $525.00
Q3 2025 -15,000 Sold Out 0 $0.00

Michael Burry's Regeneron Pharmaceuticals Investment FAQs

Michael Burry first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2025, acquiring 15,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Michael Burry has held Regeneron Pharmaceuticals, Inc. (REGN) for 2 quarters since Q2 2025.

Michael Burry's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q2 2025, adding 15,000 shares worth $7.88 M.

According to the latest 13F filing for Q3 2025, Michael Burry's firm, Scion Asset Management, LLC, owns 0 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $0.

As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.00% of Michael Burry's publicly disclosed stock portfolio, making it one of their key holdings.

Michael Burry's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 15,000 shares, as reported at the end of Q2 2025.